TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of "Hold" from Analysts

Key Points

• TScan Therapeutics has a consensus analyst rating of “Hold”, based on six covering brokerages. The average 12-month price target is $6.00, above its recent trading price.
• Recent analyst actions were mixed: Needham and Wedbush reiterated buy/outperform views, while Wall Street Zen downgraded the stock to strong sell and Weiss Ratings kept a sell rating.
• The company reported its latest quarterly EPS in line with expectations at -$0.22, but revenue of $0.98 million fell short of estimates. TScan remains a clinical-stage biotech focused on developing T-cell receptor therapies for cancer.

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have received a consensus rating of "Hold" from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $6.00.

Several analysts have recently weighed in on TCRX shares. Needham & Company LLC reissued a "buy" rating and issued a $6.00 target price on shares of TScan Therapeutics in a report on Tuesday, June 23rd. Wall Street Zen downgraded TScan Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, May 9th. Wedbush reaffirmed an "outperform" rating and set a $5.00 price target on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of TScan Therapeutics in a research note on Tuesday, April 21st.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Boothbay Fund Management LLC raised its stake in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company's stock valued at $35,000 after acquiring an additional 8,121 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of TScan Therapeutics by 6.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company's stock valued at $235,000 after purchasing an additional 9,676 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of TScan Therapeutics by 48.7% in the first quarter. Bank of America Corp DE now owns 57,529 shares of the company's stock valued at $58,000 after purchasing an additional 18,829 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of TScan Therapeutics by 8.5% in the second quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company's stock valued at $417,000 after purchasing an additional 22,642 shares during the period. Finally, Panagora Asset Management Inc. purchased a new stake in shares of TScan Therapeutics during the fourth quarter worth approximately $25,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Trading Up 1.8%

NASDAQ TCRX opened at $0.91 on Friday. The firm's fifty day moving average price is $1.00 and its 200 day moving average price is $1.06. TScan Therapeutics has a 12 month low of $0.83 and a 12 month high of $2.57. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.65 and a quick ratio of 6.65. The company has a market capitalization of $59.78 million, a price-to-earnings ratio of -0.95 and a beta of 1.04.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). The company had revenue of $0.98 million during the quarter, compared to the consensus estimate of $2.50 million. TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. On average, sell-side analysts expect that TScan Therapeutics will post -1.11 earnings per share for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan's approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company's pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.